• Skip to main content
  • Skip to footer

Histogen

  • About Us
  • Our Science
  • Investors
  • Contact
Home Hero

About Us

Working to bring life-changing options to
redefine immunotherapy

COMPANY

Developing novel, validated solutions for infectious disease treatment

We are a clinical-stage therapeutics company focused on developing potential first-in-class clinical and preclinical small molecule pan-caspase and caspase selective inhibitors that protect the body's natural process to restore immune function.

Our product candidates include emricasan, CTS-2090, and other proprietary caspase inhibitors. Currently, we are developing emricasan for acute bacterial skin and skin structure infections (ABSSSI} as well evaluating its use for other infectious diseases.

Company Right Placeholder Img

Our difference

Icon 1

Non-antibiotic solution to prevent antibiotic resistance

Icon 2

Tested, known pathway of approval and known endpoints

Icon 3

Inflammation suppression that may cure infections faster

Management team

Decades of experience in bringing cell-based regenerative products from concept to market

Mento
Steven J. Mento Ph.D.
President and CEO
Read bio
Knudson
Susan A. Knudson
EVP, COO, and CFO
Read bio
Spada
Alfred P. Spada Ph.D.
EVP and CSO
Read bio
Reyes
Joyce Reyes MAS Health Law, RAC
SVP Regulatory, Quality, Clinical and Technical Operations
Read bio
Hubka
Thomas Hubka
VP Finance
Read bio

Board of directors

Kisner
Daniel L. Kisner MD
Read bio
Crean
David H. Crean Ph.D.
Read bio
Fuhrmann
Rochelle Fuhrmann
Read bio
Jackson
Jonathan Jackson
Read bio
Mento
Steven J. Mento Ph.D.
Read bio
Satz
Brian Satz
Read bio
Windham
Susan Windham-Bannister, Ph.D.
Read bio

Information for investors

For investors

Logo V1

Contact us
858-526-3100
info@histogen.com

dashicons-twitter dashicons-linkedin

Privacy Policy | Web Accessibility | Site Map

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply

Copyright ©2023 Histogen. All Rights Reserved. Designed by TinyFrog Technologies.